Interleukin-1α-induced modulation of topoisomerase I activity and DNA damage: Implications in the mechanisms of synergy with camptothecins in vitro and in vivo

Molecular Pharmacology

Volumn 49, Issue 2, 1996, Pages 269-275

  Wang, Zheng ^a   Sinha, Birandra K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; INTERLEUKIN 1ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CHEMICAL CARCINOGENESIS; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0029671159     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Wall, M., M. C. Wani, C. E. Cook, K. H. Palmer, A. T. McPhail, and G. A. Sim Plant anti-tumor agents. I. The isolation and structure of camptothecin, a novel alkaloid leukemia and antitumor inhibitor from camptotheca acuminata. J. Am. Chem. Soc. 88:3888-3890 (1966).
2. Venditti, J. M., and B. J. Abbott. Studies on oncolytic agents from natural sources: correlation of activity against animal tumors and clinical effectiveness. Lloydia (Cinci.) 30:332-335 (1967).
3. Giovanella B. C., H. R. Hinz, A. J. Kozielski, J. S. Stehlin, Jr., R. Silber, and M. Potmesil. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-[S]-camptothecin. Cancer Res. 51:3052-3055 (1991).
4. Masuda, N., M. Fukuoka, Y. Kusunoki, K. Matsui, N. Takifuji, S. Kudda, S. Negoro, M. Nishioka, K. Nakagaw, and M Takadda. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 10:1225-1230 (1992).
5. Sinha, B. K. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 49:11-19 (1995).
6. Myers, C. E , K. H. Cowan, B. K. Sinha, and B. Chabner. The phenomenon of multidrug resistance, in Important Advances in Oncology (V. T. DeVita, Jr, S. Hellman, and S. Rosenberg, eds.). J.B Lippincott, Philadelphia, 27-38 (1987).
7. Gottesman, M. M., and I Pastan, Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol. Sci. 9:54-58 (1988).
8. Spriggs, D. R., M. L. Sherman, H. Michie, K. A. Arther, K. Imamra, D. Wilmore, E. Frie III, and D. W. Kufe. Recombinant human tumor necrosis factor administered as a 24 hour intravenous infusion: a phase I and pharmacologic study. J. Natl. Cancer Inst 80:1039 (1988).
9. Weidenmann, B., P. Reichardt, U. Rath, L. Theilman, B. Schule, A, D. Ho, E. Schlick, J. Kempeni, and B. Kommerall. Phase I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J. Cancer Res. Clin Oncol. 115:189-192 (1989).
10. Mitchell, M. S. Combining chemotherapy with biological response modifiers in treatment of cancer. J. Natl. Cancer Inst. 80:1445-1450 (1988).
11. Wadler, S., and E. L. Schwartz. Antineoplastic activity of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 50:3473-3486 (1990).
12. Lachman, L. B., C. A. Dinarello, N. D. Llansa, and I. Fidler. Natural and recombinant human interleukin 1β is cytotoxic for human melanoma cells. J. Immunol. 136:3098-3102 (1986).
13. Last-Barney, K. C., A. Homon, R. B. Faanes, and V. J. Merluzzi. Synergistic and overlapping activities of tumor necrosis factor α and IL-1. J. Immunol. 141:527-530 (1988).
14. Le, J., and J. Vilcek. Biology of disease: tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest. 56:234-248 (1987).
15. Dinarello, C. Biology of interleukin 1. FASEB J. 2:108-115 (1988).
16. Onozaki, K., K. Mastushima, B. B. Aggarwal, and J. J. Oppenheim. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J. Immunol. 135:3962-3968 (1985).
17. Paciotti, G. F., and L. Tamarkin. Interleukm-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol. Endocrinol. 2:459-464 (1988).
18. Braunschweiger, P. G., C. S. Johnson, N. Kumar, V. Ord, and P. Furmanski. Antitumor effects of recombinant human interleukin 1α in RIF-1 and Panc02 solid tumors. Cancer Res. 48:6011-6016 (1988).
19. Dower, S. K., S. R. Kronheim, C. J. March, P. J., Conlon, T. P. Hopp, S. Gillis, and D. L. Urdal. Detection and characterization of high affinity plasma membrane receptor for human interleukin 1. J. Exp. Med. 162: 501-515 (1985).
20. Usui, N., E. G. Mimnaugh, and B. K. Sinha. Synergistic antitumor activity of etoposide and human interleukin-1α against human melanoma cells. J. Natl. Cancer Inst. 81:1904-1909 (1989).
21. Usui, N., E. G. Mimnaugh, and B. K. Sinha. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin-1α and etoposide against human melanoma cells. Cancer Res. 51:769-774 (1991).
22. Mimnaugh, E. G., E. Monti, S. Sebers, M. Stetler-Stevenson, and B. K. Sinha. Synergistic antiproliferative effects of the combination of human interleukin-1α and doxorubicin against human melanoma cells. Oncol. Res. 4:401-412 (1992).
23. Kilian, P. L., K. L. Kaffka, D. A. Biondi, J. M. Lipman, W. R. Benjamin, D. Feldman, and C. A. Campden. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3). Cancer Res. 51:1823-1828 (1991).
24. Monti, E., E. G. Mimnaugh, and B. K. Sinha. Synergistic antiproliferative effects of interleukin-1α and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3). Biochem. Pharmacol. 45:2099-2107 (1993).
25. Hamilton, T. C., R. C. Young, K. R. McKoy, J. A. Green, E. W. Chu, J. Whang-Peng, A. M. Rogan, W. R. Green, R. F. Ozols. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors Cancer Res. 43:5379-5389 (1983)
26. Benchekroun, M. N., R. Parker, E. Reed, and B K. Sinha. Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin 1α. Biochem. Biophys. Res. Commun. 195:294-300 (1993).
27. Wang, Z., M. N. Benchekroun, and B. K. Sinha. Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1α against human ovarian carcinoma in vivo. Anticancer Res. 14:1723-1726 (1994).
28. Alley, M C., D. A Scudiero, A. Monks, M L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Schoemaker, and M. R. Boyd. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer. Res. 48:589-601 (1988).
29. Chou, T.-C., and P. Talalay. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55 (1983).
30. Sinha, B. K., and H. M. Eliot. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors. Biochim. Biophys. Acta 1097:111-116 (1991)
31. Rowe, T. C., G L Chen, Y. H. Hsiang, and L. F. Liu. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46:2021-2026 (1986).
32. Yamazaki, H., E. Scheinder, C. E. Myers, and B. K. Sinha. Oncogene expression and de novo drug-resistance in human prostate cancer cells. Biochim. Biophys. Acta 1226:89-96 (1994).
33. Sinha, B K., H. Yamazaki, H. M. Eliot, E. Schneider, M. M. Borner, and P. M O'Connor. Relationship between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim. Biophys. Acta 1270:12-18 (1995).
34. Politi, P. M., and B. K. Sinha. Role of differential drug uptake, efflux and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanism of drug resistance. Mol. Pharmacol. 35: 271-278 (1988).
35. Tomayko M. M., and C. P. Reynolds. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24: 148-154 (1989).
36. Li, B.-Y., D. Mohanraj, M. C. Olson, M. Moradi, L. Twiggs, L. F. Carson, and S. Ramakrishnan. Human ovarian epithelial cancer cells cultured in vitro express both interleukin 1α and β genes. Cancer Res. 52:2248-2252 (1992).
37. Slichenmyer, W. J , E. K. Rowinsky, R C. Donehower, and S. H. Kauffman. The current status of camptothecin and analogues as antitumor agents. J. Natl. Cancer Inst. 85:271-291 (1993).
38. Rowinsky, E. K., L. B Grochow, C. B. Hendricks, D. S. Ettinger, A. A. Forastier, L. A. Hurowitz, W. P. McGuire, S. E. Sartorius, B. G. Lubejko, S. H. Kauffman, and R. C. Donehower. Phase I and pharmacological studies of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. 10:647-656 (1992).
39. Hsiang, Y. H., R. Hertzberg, S. Hect, and L. F. Lui. Camptothecin induces protein-linked DNA breaks via mammalian topoisomerase I. J. Biol. Chem. 260:14873-14878 (1985).
40. Pommier, Y., D. Kerrigan, K. D Hartman, and R I. Glazer. Phosphorylation of mammalian DNA topoisomerase I and activation by protein C. J. Biol. Chem. 16:9418-9422 (1990).
41. A. Raz, A Wyche, and P Needleman. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and transnational phases. Proc. Natl. Acad. Sci. USA 86:1657-1661 (1989).
42. Kawato, Y., M. Aonuma, Y. Hirota, H. Kuga, and K. Sato. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51:4187-4191 (1991).
43. Braunschweiger, P. G., A. S. Jones, C. J. Johnson, and P. Furmanski. Sensitization of solid tumors to benzotriazine dioxide (SR 4233) by interleukin 1α. Proc. Am Assoc. Cancer Res. 32:2451 (1991).
44. Braunschweiger, P G., A. S. Jones, C. J. Johnson, and P. Furmanski Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin-1α. Cancer Res. 51: 5454-5460 (1991).
45. Epstein, D. A., C. G. Kurahara, N. A. Bruno, and T. G. Terrell. Prevention of doxorubicin-induced hepatotoxicity in mice by interleukin-1. Cancer Res. 49:3955-3960 (1989).